Uday Kumar P1, Ashok Reddy K1, Rao SC2, Srinivasulu G3 and Bhanuprakash Reddy G1
Posters Accepted Abstracts: J Cancer Sci Ther
Background: Cancer is one of the leading causes of human morbidity and mortality around the world and breast cancer, commonest in females. The Aldo-keto-reductase (AKR) family has about 140 proteins including Aldose reductase (AR or AKR1B1) and AR like proteins (AKR1B10). AR is the rate-limiting polyol pathway enzyme that converts glucose into sorbitol and is known to be involved in the secondary complications of diabetes.AR is also upregulated in many cancer cells and is thought to be involved in their resistance to chemotherapeutic drugs. Objectives:To studythe Specific activity of AR in RBCs and the Specific activity and expression of AR and AKR1B10 in breast tumorand non-tumor areas. Methodology:Whole blood samples were collected from 60 breast cancer patients and 60 non-cancer controls.A total of 100 fresh post-surgical tumor tissues, which also included 25 benign tumors were obtained. AR activity was studied in RBCs while both AR and AKR1B10 were studied by immunoblotting [for expression] and enzyme activity studies in tissue samples. Histopathology evaluation for typing and grading of tumors was also done. Statistical analysis was done usingMann-Whitney U- test. Results: Specific activity of AR in RBCs of all cancer patients (of all grades)was significantly increased compared to benign and controls. Specific activity and expression of ARand AKR1B10 levels were increased in tumors compared to non- tumor samples. Conclusions: Our study indicates for the first timethat increased AR activity levels in RBCs correlated with increased levels in tumorsand may be useful as an indicator to denote a possible development of breast cancer, which could alert the individual to seek medical opinion at an early stage and improve quality of life in such subjects.
Cancer Science & Therapy received 3968 citations as per Google Scholar report